COMMUNIQUÉS West-GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

28/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: [...]

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

28/08/2024 - 14:00

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at [...]

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28/08/2024 - 14:00

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

28/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its [...]

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

28/08/2024 - 14:00

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range [...]

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28/08/2024 - 14:00

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26 th Annual Global [...]

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

28/08/2024 - 14:00

STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]

Prime Medicine to Participate in Upcoming Investor Conferences

28/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

28/08/2024 - 14:00

- Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - Results [...]

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

28/08/2024 - 14:00

Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer- [...]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

28/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and [...]

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

28/08/2024 - 14:00

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28/08/2024 - 14:00

Long-term safety and tolerability profile consistent with pivotal data in atopic dermatitis (AD), with no new safety signals observed during 56 weeks of treatment Results from open-label extension study highlight that [...]

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

28/08/2024 - 14:00

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]

Biora Therapeutics Announces Positive Nasdaq Listing Decision

28/08/2024 - 14:00

Company granted extension to regain compliance with Nasdaq listing requirements SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery [...]

Safety Shot Announces Partnership with Digital Growth Platform VENDO

28/08/2024 - 14:00

As Masters in the E-Commerce Space VENDO is Anticipated to Significantly Help to Grow the Safety Shot Brand Online. JUPITER, Fla., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Safety Shot , Inc. (Nasdaq: SHOT) (“Safety Shot” or “ [...]

Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

28/08/2024 - 13:30

In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s SUNNYVALE, Calif., Aug. 28, [...]

BridgeBio Pharma to Participate in September Investor Events

28/08/2024 - 13:30

PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the [...]

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

28/08/2024 - 13:07

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Biosciences The once-daily 20 mg dose [...]